Could a simple blood test tell some breast cancer patients It's safe to stop treatment?

NCT ID NCT06663787

Ongoing Knowledge-focused Sponsor: Nagoya City University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The goal is to see if this test can help guide future decisions about continuing or stopping treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab (Herceptin) and other anti-HER2 drugs
What this could lead to: If successful, this could help doctors decide whether some patients can safely stop or reduce their anti-HER2 therapy, potentially reducing side effects and treatment burden.
What could go wrong: This is a small, observational study (50 people) that only measures DNA in the blood—it does not test whether changing treatment is safe. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma Her2-receptor negative breast cancer Neoplasm Metastasis Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC HER2 + BREAST CANCER

Contacts and locations

Locations

Aichi Cancer Center

Nagoya, Aichi-ken, 4678601, Japan
Nagoya City University

Nagoya, Aichi-ken, 4678601, Japan
Natera

San Carlos, Texas, 94070, United States
The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Tokyo, Tokyo, 135-8550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.